Blog Posts

Nov 15, 2024, 16:14

Epco in first line older Diffuse large B-cell lymphoma

Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared on X:

“Epco in 1L older DLBCL:

– 45 patients, med age 81, 58% IPI 3+

– ORR 74%, CR 64%, 6-mo OS 76%

– 16% d/c’d d/t TEAEs, 4 G5 events!

– low rates G3 CRS/ICANS

Still early f/u (50% still on tx) but promising time-limited approach for multimorbid/frail. ”

Paper: Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older, Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Authors: Franck Morschhauser, David Belada, Johannes Duell, Wojciech Jurczak, Tae Min Kim, Won Seog Kim, Takahiro Kumode, Javier Lopez Jimenez, Caressa Meert, Sergio Ortegon Alcaide, Catherine Thieblemont, Yajian Jiang, Mina Khoshdeli, Yanli Wang, Evelyn Guo, Daniela Hoehn, and Sherida Woei-A-Jin

Epco in first line older Diffuse large B-cell lymphoma

Ajay Major and Sherida Woei-A-Jin cancer Caressa Meert Catherine Thieblemont Daniela Hoehn David Belada Evelyn Guo Javier López-Jiménez Johannes Duell Mina Khoshdeli OncoDaily Oncology ranck Morschhauser Sergio Ortegon Alcaide Tae Min Kim Takahiro Kumode Wojciech Jurczak Won Seog Kim Yajian Jiang Yanli Wang

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech